CG Oncology Future Growth
Future criteria checks 2/6
CG Oncology is forecast to grow earnings and revenue by 17.1% and 61.9% per annum respectively. EPS is expected to grow by 43.5% per annum. Return on equity is forecast to be -42.5% in 3 years.
Key information
17.1%
Earnings growth rate
43.5%
EPS growth rate
Biotechs earnings growth | 24.8% |
Revenue growth rate | 61.9% |
Future return on equity | -42.5% |
Analyst coverage | Low |
Last updated | 13 May 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 95 | -99 | -143 | N/A | 4 |
12/31/2025 | 11 | -112 | -144 | N/A | 3 |
12/31/2024 | 2 | -88 | -107 | N/A | 4 |
3/31/2024 | 1 | -72 | -64 | -64 | N/A |
12/31/2023 | 0 | -68 | -46 | -46 | N/A |
9/30/2023 | 0 | -58 | -36 | -36 | N/A |
12/31/2022 | 0 | -44 | -30 | -30 | N/A |
12/31/2021 | 10 | -18 | -14 | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CGON is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CGON is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CGON is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CGON's revenue (61.9% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: CGON's revenue (61.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CGON is forecast to be unprofitable in 3 years.